Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia [preprint]
Authors
Funes, SalomeGadd, Del Hayden
Mosqueda, Michelle
Zhong, Jianjun
Jung, Jonathan
Shankaracharya
Unger, Matthew
Cameron, Debra
Dawes, Pepper
Keagle, Pamela J
McDonough, Justin A
Boopathy, Sivakumar
Sena-Esteves, Miguel
Lutz, Cathleen
Skarnes, William C
Lim, Elaine T
Schafer, Dorothy P
Massi, Francesca
Landers, John E
Bosco, Daryl A
Student Authors
Salome FunesMichelle Mosqueda
Jonathan Jung
Matthew Unger
Academic Program
Translational Science; Biochemistry and Molecular Biotechnology; NeuroscienceUMass Chan Affiliations
Biochemistry and Molecular BiotechnologyBrudnick Neuropsychiatric Research Institute
Horae Gene Therapy Center
Microbiology and Physiological Systems
Molecular, Cell and Cancer Biology
Morningside Graduate School of Biomedical Sciences
Neurobiology
Neurology
Program in Bioinformatics and Integrative Biology
Schafer Lab
Document Type
PreprintPublication Date
2023-06-01
Metadata
Show full item recordAbstract
Microglia play a pivotal role in neurodegenerative disease pathogenesis, but the mechanisms underlying microglia dysfunction and toxicity remain to be fully elucidated. To investigate the effect of neurodegenerative disease-linked genes on the intrinsic properties of microglia, we studied microglia-like cells derived from human induced pluripotent stem cells (iPSCs), termed iMGs, harboring mutations in profilin-1 (PFN1) that are causative for amyotrophic lateral sclerosis (ALS). ALS-PFN1 iMGs exhibited lipid dysmetabolism and deficits in phagocytosis, a critical microglia function. Our cumulative data implicate an effect of ALS-linked PFN1 on the autophagy pathway, including enhanced binding of mutant PFN1 to the autophagy signaling molecule PI3P, as an underlying cause of defective phagocytosis in ALS-PFN1 iMGs. Indeed, phagocytic processing was restored in ALS-PFN1 iMGs with Rapamycin, an inducer of autophagic flux. These outcomes demonstrate the utility of iMGs for neurodegenerative disease research and highlight microglia vesicular degradation pathways as potential therapeutic targets for these disorders.Source
Funes S, Gadd DH, Mosqueda M, Zhong J, Jung J, Shankaracharya, Unger M, Cameron D, Dawes P, Keagle PJ, McDonough JA, Boopathy S, Sena-Esteves M, Lutz C, Skarnes WC, Lim ET, Schafer DP, Massi F, Landers JE, Bosco DA. Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia. bioRxiv [Preprint]. 2023 Jun 1:2023.06.01.541136. doi: 10.1101/2023.06.01.541136. PMID: 37398081; PMCID: PMC10312575.DOI
10.1101/2023.06.01.541136Permanent Link to this Item
http://hdl.handle.net/20.500.14038/52415PubMed ID
37398081Notes
This article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.Related Resources
Now published in Nature Communications doi: 10.1038/s41467-024-46695-wRights
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.ae974a485f413a2113503eed53cd6c53
10.1101/2023.06.01.541136